ReviewPharmacogenetics and genomics2014
Comparison of delivery strategies for pharmacogenetic testing services.
Review in Pharmacogenetics and genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Case Report: Clinical implications ofFrontiers in pediatrics · 2026Article
- Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation.Pharmacogenomics · 2023Article
- Pharmacogenetics of Antiplatelet Therapy.Annual review of pharmacology and toxicology · 2023Review
- Mental Health Prescribers' Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region.Pharmacogenomics and personalized medicine · 2023Article
- Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Annual review of genomics and human genetics · 2022Review
- Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models.Pharmacogenomics · 2021Review
- Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting.Journal of personalized medicine · 2021Article
- Strategies to Improve the Clinical Outcomes for Direct-to-Consumer Pharmacogenomic Tests.Genes · 2021Review
- Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.Pharmacogenomics and personalized medicine · 2021Article
- Physicians' Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study.Pharmacogenomics and personalized medicine · 2021Article
- DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.Pharmacotherapy · 2020Review
- A stepwise approach to implementing pharmacogenetic testing in the primary care setting.Pharmacogenomics · 2019Article
- VA Primary Care and Mental Health Providers' Comfort with Genetic Testing: Survey Results from the PRIME Care Study.Journal of general internal medicine · 2019Article
- Pharmacogenomics courses in pharmacy school curricula.Pharmacogenomics · 2019Article
- Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer.Innovations in pharmacy · 2019Article
- Knowledge And Attitudes Of Pharmacy Students Towards Pharmacogenomics Among Universities In Jordan And West Bank Of Palestine.Pharmacogenomics and personalized medicine · 2019Article
- User considerations in assessing pharmacogenomic tests and their clinical support tools.NPJ genomic medicine · 2018Review
- Qualitative user evaluation of a revised pharmacogenetic educational toolkit.Pharmacogenomics and personalized medicine · 2018Article
- Prevalence of clinically actionable genotypes and medication exposure of older adults in the community.Pharmacogenomics and personalized medicine · 2017Article
- A review of consent practices and perspectives for pharmacogenetic testing.Pharmacogenomics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The number and use of pharmacogenetic tests to assess a patient's likelihood of response or risk of an adverse event is expanding across medical specialties and becoming more prevalent. During this period of development and translation, different approaches are being investigated to optimize delivery of pharmacogenetic services. In this paper, we review pre-emptive and point-of-care delivery approaches currently implemented or being investigated and discuss the advantages and disadvantages of each approach. The continued growth in knowledge about the genetic basis of drug response combined with development of new and less expensive testing technologies and electronic medical records will impact future delivery systems. Regardless of delivery approach, the currently limited knowledge of health professionals about genetics generally or PGx specifically will remain a major obstacle to utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.